Four months after going public on the strength of its GR-II receptor antagonists, Corcept Therapeutics Inc. reached agreement on a special protocol assessment for pivotal Phase III trials to test its lead product Corlux (mifepristone) against the psychotic features of major depression. (BioWorld Today)